ChatGPTなどを活用して業務のAI化を進めています。プロンプトエンジニアリングの専門家です！と、名乗れるレベルではありませんが、かなり色々使いこなしてきています。病気で失われた能力は、別な能力を発達させる、進化することで生き残っていこうと思います。
<><><>
<>
25/01/25
[HTML] Identifying outcome domains to establish a core outcome set for progressive pulmonary fibrosis: a scoping review
A Delameillieure, V Somogyi, S Schenk, N Toreyin… - European Respiratory …, 2025
… Idiopathic pulmonary fibrosis (IPF) is a rare disease defined by an ultimately progressive and irreversible development of pulmonaryfibrosis… Recently, fibrosing interstitial lung diseases (ILDs) with a progressive phenotype have been …
- 進行性肺線維症のコアアウトカムセットを確立するためのアウトカムドメインの特定：スコープレビュー
… transcriptome analysis revealing mechanotransduction via the Hippo/YAP pathway in promoting fibroblast-to-myofibroblast transition and idiopathic pulmonary fibrosis …
J Lu, Z Wang, L Zhang - Gene, 2025
Objective Idiopathic pulmonary fibrosis (IPF) is an irreversible and fatal interstitial lung disease, characterized by excessive extracellular matrix (ECM) secretion that disrupts normal alveolar structure. This study aims to explore the potential molecular …
[PDF] Mortality rate in chronic fibrosing idiopathic interstitial pneumonia: the role of lung cancer
BM Chacón, LA Alcázar, JLÁS Walther, MAN Barbero - 2025
… Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil HE cacy of anti brotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary brosis in both idiopathicpulmonary brosis (IPF) and non-IPF: a systematic review and meta-analysisBMC …
- 慢性線維化特発性間質性肺炎の死亡率：肺がんの役割
[HTML] Performance of the FORD Versus Other Available Models for the Noninvasive Prediction of Pulmonary Hypertension in Patients with Interstitial Lung Disease
HC Kim, A Chandel, CS King, MJ Kim, M Shawabkeh… - Lung, 2025
… Some of these have been combined in prediction formulas including the FORD model which was derived and validated in patients with idiopathic pulmonary fibrosis (IPF). The FORD model has demonstrated very good performance …
- 間質性肺疾患患者における肺高血圧症の非侵襲的予測における FORD と他の利用可能なモデルの性能の比較
Piezo2 is a key mechanoreceptor in lung fibrosis that drives myofibroblast differentiation
MAT Freeberg, SV Camus, V Robila, A Perelas… - The American Journal of …, 2025
… Idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic interstitial lung disease … patients with IPF and mouse tissue from bleomycin induced pulmonary fibrosis was assessed. … Piezo2 expression is upregulated in tissue from patients …
- Piezo2は肺線維症における重要な機械受容体であり、筋線維芽細胞の分化を促進する。
[HTML] The fibronectin-targeting PEG-FUD imaging probe shows enhanced uptake during fibrogenesis in experimental lung fibrosis
TJ Harr, N Gupta, B Rahar, K Stott, Y Medina-Guevara… - Respiratory Research, 2025
… Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible form of interstitial lung disease (ILD) with median survival duration of 2 … Based on our previous findings with IPFtissue ex vivo, we hypothesized that PEG-FUD may target …
- フィブロネクチンを標的としたPEG-FUDイメージングプローブは、実験的肺線維症における線維形成中に取り込みが促進されることを示した。
High-Resolution CT: The Cutting-Edge Tool Transforming Interstitial Lung Disease Diagnosis
R Mugundan, SH Anand, P Ramegowda - International Medicine ISSN: 2667-7008, 2024
… Idiopathic Pulmonary Fibrosis (IPF) was the most frequent diagnosis, comprising 28.57% of cases. The study population had a balanced gender distribution, with a predominance of middle-aged and older adults. Smoking was notably prevalent in …
- 高解像度CT：間質性肺疾患の診断を変革する最先端のツール
Glycobiology and Glycosylation: Deciphering the Secrets of Glycans in Humans and Pathogens
P Jabbarzadeh Kaboli, C Proestos - Frontiers in Immunology
… of fibrosis in idiopathic pulmonary fibrosis(IPF).Their findings reveal significantly elevated levels of OGT in IPF patients, implicating OGT in … This discovery positions OGT as a potential therapeutic target for IPF and other fibrotic diseases …
- 糖鎖生物学と糖鎖付加：ヒトと病原体の糖鎖の秘密を解読する
A Review On Itepekimab: An Investigational Drug
F Shaikh, GJ Khan, R Deshmukh, A Shaikh… - International Journal of …, 2025
… A number of biologic medicines are presently under development to treat pulmonary sarcoidosis, idiopathic pulmonary fibrosis, asthma, and chronic obstructive pulmonary disease. With an emphasis on the results of randomized …
- イテペキマブのレビュー：治験薬 (IL-33標的)
25/01/23
[HTML] Genetic variation reveals the therapeutic potential of BRSK2 in idiopathic pulmonary fibrosis
Z Chen, M Tang, N Wang, J Liu, X Tan, H Ma, J Luo… - BMC Medicine, 2025
… and treatment strategies for idiopathicpulmonary fibrosis (IPF). This study aimed to identify key targets involved in the progression of IPF. … and peripheral blood mononuclear cells (PBMCs) from idiopathic pulmonary fibrosis(IPF) patients and …
- 遺伝的変異により、特発性肺線維症におけるBRSK2の治療効果が明らかに
<>
<><><>
特発性肺線維症( idiopathic pulmonary fibrosis (IPF) )関連の学術的情報収集してシェアしています。Google Scholar SearchのUpdateを定期的に掲載しています。GoogleのAIが一定の重み付けはしているとは思いますが、玉石混交です。
当面、毎週アラートの内容をアップしていこうと思います。
###
